Nicolas Roberto Robles
Overview
Explore the profile of Nicolas Roberto Robles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cerezo I, Cancho B, Rodriguez Sabillon J, Jorge A, Alvarez Lopez A, Valladares J, et al.
J Clin Lab Anal
. 2024 Dec;
39(2):e25139.
PMID: 39713962
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta-2-microglobulin (B2M) and...
2.
Wojciechowska W, Rajzer M, Kreutz R, Weber T, Bursztyn M, Persu A, et al.
J Hypertens
. 2024 Sep;
42(12):2065-2074.
PMID: 39248094
Background: We aimed to determine the influence of coronavirus disease 2019 (COVID-19) pandemic on blood pressure (BP) control assessed by ambulatory blood pressure monitoring (ABPM). Methods: Office BP and ABPM...
3.
Halimi J, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, et al.
Blood Press
. 2024 Jun;
33(1):2368800.
PMID: 38910347
Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A...
4.
Halimi J, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, et al.
J Hypertens
. 2024 May;
42(9):1544-1554.
PMID: 38747416
Objective: Real-life management of hypertensive patients with chronic kidney disease (CKD) is unclear. Methods: A survey was conducted in 2023 by the European Society of Hypertension (ESH) to assess management...
5.
Robles N, Fici F, Grassi G
J Hum Hypertens
. 2024 Mar;
38(4):295-297.
PMID: 38514866
No abstract available.
6.
Cancho B, Alvarez Lopez A, Valladares J, Rodriguez Sabillon J, Lopez Gomez J, Robles N
Med Clin (Barc)
. 2024 Feb;
162(11):511-515.
PMID: 38388320
Objectives: Cystatin C is increasingly used as a marker of renal function as a complement to serum creatinine and glomerular filtration rate (GFR). We have assessed its efficacy as a...
7.
Bermejo S, Gonzalez E, Lopez-Revuelta K, Ibernon M, Lopez D, Martin-Gomez A, et al.
Clin Kidney J
. 2023 Oct;
16(10):1656-1663.
PMID: 37779839
Background: Up to 50-60% of patients with diabetes have non-diabetic kidney disease (NDKD) on kidney biopsy. Diabetic retinopathy (DR) is a microvascular complication of diabetes frequently associated with diabetic nephropathy...
8.
Martinez V, Furlano M, Sans L, Pulido L, Garcia R, Perez-Gomez M, et al.
Clin Kidney J
. 2023 Jun;
16(6):985-995.
PMID: 37260991
Background: The clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD) usually appear in adulthood, however pediatric series report a high morbidity. The objective of the study was to analyze...
9.
Fici F, Robles N, Tengiz I, Grassi G
High Blood Press Cardiovasc Prev
. 2023 May;
30(3):191-198.
PMID: 37166681
Introduction: International guidelines have removed b-blockers from first-line treatment of hypertension, limiting their use to patients with compelling indications. The position of guidelines stems from the results of studies performed...
10.
Robles N, Alvarez A, Fici F
Eur J Intern Med
. 2023 Mar;
111:21-23.
PMID: 36931973
No abstract available.